-The Hindu The Election Commission on Wednesday said that paid news was a very "complex problem" and it had taken the issue seriously to ensure a level-playing field to all political parties and candidates in the elections to the Legislative Assembly on May 5. Addressing a media workshop on electoral process here, Director-General at the Election Commission, Akshay Rout, said: "Paid news is a complex issue and it had disturbed the political...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-The Hindu But both police and Tritiya Prastuti Committee deny claim Kunda (Jharkhand): All through Monday and Tuesday, cadres of the Tritiya Prastuti Committee (TPC), a splinter group of the banned CPI (Maoist), in the Sarengdah and Kunda panchayats in Chatra district kept track of what their leaders decided to do with the 25 Maoists taken hostage four days ago. In the March 29 attack, the TPC also killed 10 Maoists after...

-The Hindu   Despite apparent similarities, the Reports of two centrally appointed committees are split on the relationship between knowledge, skills and social needs Two major Reports with overlapping concerns were submitted to the central government during the last decade. They were drafted by committees appointed by two different offices of the same government. One was chaired by Yash Pal, and the other by Sam Pitroda. The titles of the two committees indicated...

-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature Reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...